S&P 500
5,914.48
+1.9%
+$111.66
DJI
42,297.46
+1.7%
+$694.39
NASDAQ
19,159.21
+2.3%
+$422.00
Bitcoin
109,909.00
+0.7%
+761.06
AAPL
$200.34
+2.6%
+$5.07
AMZN
$205.25
+2.1%
+$4.26
GOOG
$173.71
+2.4%
+$4.12
META
$640.82
+2.2%
+$13.76
MSFT
$459.66
+2.1%
+$9.48
NVDA
$135.04
+2.9%
+$3.75
TSLA
$358.94
+5.8%
+$19.60
Adlai Nortye (NASDAQ: ANL)
$1.85
(0.0%)
$0.00
Price as of May 27, 2025, 11:54 a.m. ET
Adlai Nortye Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adlai Nortye Company Info
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.